A controlled register-based study of 460 neurofibromatosis 1 patients: Increased fracture risk in children and adults over 41 years of age

Journal of Bone and Mineral Research

Volumn 27, Issue 11, 2012, Pages 2333-2337

  Heervä, Eetu ^a   Koffert, Anna ^b   Jokinen, Elina ^a   Kuorilehto, Tommi ^c   Peltonen, Sirkku ^b   Aro, Hannu T ^b   Peltonen, Juha ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

CANCER; EPIDEMIOLOGY; FRACTURES; PSEUDARTHROSIS; RAS

Indexed keywords

ADOLESCENT; ADULT; AGED; ANKLE FRACTURE; APPENDECTOMY; ARTICLE; BONE DENSITY; BREAST CANCER; CHILD; CLAVICLE FRACTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELBOW FRACTURE; FEMALE; FEMUR FRACTURE; FINGER FRACTURE; FINLAND; FRACTURE; FRACTURE NONUNION; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; ICD-10; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; OSTEOPENIA; OSTEOPOROSIS; PELVIS FRACTURE; PRESCHOOL CHILD; PROSTATE CANCER; PSEUDARTHROSIS; RIB FRACTURE; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SKIN CANCER; SKULL FRACTURE; TIBIA FRACTURE; WRIST FRACTURE;

ADULT; BONE DENSITY; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; FINLAND; FRACTURE HEALING; FRACTURES, BONE; HUMANS; INCIDENCE; MALE; NEOPLASMS; NEUROFIBROMATOSIS 1; PSEUDARTHROSIS; REGISTRIES; RISK FACTORS;

EID: 84867520705     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1685     Document Type: Article

References (23)

1. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A., International Osteoporosis Foundation; National Osteoporosis Foundation. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002; 13 (7): 527-36. (Pubitemid 34790624)
2. Järvinen TL, Sievänen H, Khan KM, Heinonen A, Kannus P., Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008; 336 (7636): 124-6. (Pubitemid 351211962)
3. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285 (6): 785-95.
4. Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S, Bishop NJ, Leonard MB, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS., Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int. 2008; 19 (10): 1369-78.
5. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M., National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62 (2): 105-8.
6. Rachner TD, Khosla S, Hofbauer LC., Osteoporosis: now and the future. Lancet. 2011; 377 (9773): 1276-87.
7. Riccardi VM, Eichner JE., Neurofibromatosis: phenotype, natural history and pathogenesis. Baltimore, MD: Johns Hopkins University Press; 1992.
8. Lammert M, Friedman J, Kluwe L, Mautner V., Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005; 141 (1): 71-4. (Pubitemid 40144442)
9. Jouhilahti EM, Peltonen S, Heape AM, Peltonen J., The pathoetiology of neurofibromatosis 1. Am J Pathol. 2011; 178 (5): 1932-9.
10. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988; 45: 575-8.
11. Friedman J, Riccardi V., Clinical and epidemiological features. In:, Gutmann D, MacCollin M, Riccardi VM, editors. Neurofibromatosis: phenotype, natural history, and pathogenesis. Baltimore, MD: John Hopkins University Press; p. 26-86. 1999.
12. Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, Crawford AH, Friedman JM, Little D, Peltonen J, Carey JC, Feldman D, Yu X, Armstrong L, Birch P, Kendler DL, Mundlos S, Yang FC, Agiostratidou G, Hunter-Schaedle K, Stevenson DA., Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A. 2009; 149A (10): 2327-38.
13. Evans DG, O'Hara C, Wilding A, Ingham SL, Howard E, Dawson J, Moran A, Scott-Kitching V, Holt F, Huson SM., Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011; 19 (11): 1187-91.
14. Kuorilehto T, Pöyhönen M, Bloigu R, Heikkinen J, Väänänen K, Peltonen J., Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int. 2005; 16 (8): 928-36. (Pubitemid 41127102)
15. Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis RA, Plon SE, Phillips WA, O'Brian Smith E, Ellis KJ, Lee B., Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab. 2008; 94 (1): 105-11.
16. Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse HP, Mautner VF, Friedman JM., Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet. 2009; 46 (4): 259-65.
17. Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE, Schinke T, Mautner VF, Amling M., High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int. 2010; 21 (1): 119-27.
18. Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G, Formicuccia MC, D'Erasmo E, Calvieri S, Letizia C., Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res. 2012; 304 (4): 325-31.
19. Heervä E, Peltonen S, Svedström E, Aro HT, Väänä nen K, Peltonen J., Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone. 2012; 50 (3): 798-803.
20. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, Dube B, Viskochil DH., Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr. 2007; 150 (1): 83-8. (Pubitemid 44937722)
21. Stevenson DA, Viskochil DH, Carey JC, Slater H, Murray M, Sheng X, D'Astous J, Hanson H, Schorry E, Moyer-Mileur LJ., Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomography. Bone. 2009; 44 (4): 585-9.
22. Kolanczyk M, Kühnisch J, Kossler N, Osswald M, Stumpp S, Thurisch B, Kornak U, Mundlos S., Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Med. 2008; 6: 21.
23. Johnson BA, MacWilliams BA, Carey JC, Viskochil DH, D'Astous JL, Stevenson DA., Motor proficiency in children with neurofibromatosis type 1. Pediatr Phys Ther. 2010; 22 (4): 344-38.